Caroline Seymour | Authors


CA-125 Tracking Has Potential to Identify Disease Progression on Olaparib and Bevacizumab in Ovarian Cancer

March 20, 2021

CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin), according to an analysis from the phase 3 PAOLA-1 that was presented at the SGO 2021 Annual Meeting on Women’s Cancer.

Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC

February 24, 2021

In with EGFR-mutant non–small cell lung cancer and brain metastases, oral osimertinib achieved rapid, high, and uniform brain exposure which was followed reduction in total brain metastases volume, according to results from the phase 1 ODIN-BM study.

Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC

January 31, 2021

Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.

Urelumab Combo Leads to Improved Pathologic Response in Resectable PDAC

January 25, 2021

Improved antitumor activity of the triplet combination of urelumab, a GVAX vaccine, and nivolumab was observed in patients with resectable pancreatic ductal adenocarcinoma, according to findings from a 3-arm phase 1/2 trial.